AstraZeneca unveils expanded manufacturing facility in Texas

Core Insights - AstraZeneca has unveiled a $445 million expanded manufacturing facility in Coppell, Texas, aimed at doubling the production of Lokelma for global distribution [1][2][3] Investment and Expansion - The $445 million investment is part of AstraZeneca's broader $50 billion commitment to US R&D and manufacturing over the next five years, announced in July 2025 [2][9] - The expansion includes a new 9,000 square foot building, adding two novel manufacturing lines and enhancing laboratory testing, warehousing, and administrative space [3] Workforce and Economic Impact - The Coppell facility is the sole global manufacturing site for Lokelma, serving over 50 countries and employing more than 250 people [3] - AstraZeneca's US operations support over 100,000 jobs nationwide, with a workforce exceeding 25,000 [5] Community Engagement - At the unveiling event, AstraZeneca's STEM education partner, Learning Undefeated, showcased an interactive mobile lab to inspire students about careers in manufacturing [4]